1. Scrip
  2. >>Drug Pricing

Mylan's Generic EpiPen: A Good PR Move, But Risks Alienating Payers

 
• By Donna Young

Mylan's plan to provide a generic version of its emergency allergic reaction drug EpiPen may be a good PR move, but it may alienate payers further. It also has spurred new skepticism about the company's pricing practices.

Mylan NV's plan to launch its own generic version of its emergency allergic reaction drug EpiPen (epinephrine) wasn't enough to stave off the critics over the branded product's $608 list price or blunt the moxie of a compounder looking to bring a much lower cost alternative to patients.

Mylan's move would, nonetheless, potentially keep the company somewhat ahead of any potential rivals aiming to take a bite out...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Drug Pricing

BIO Notebook: MFN Pricing, Next-Gen Obesity R&D, FDA’s Rare Disease Hub & Reaction To Review Program

 
• By Sarah Karlin-Smith, Mandy Jackson, and Alaric DeArment

Highlights from Day 3 of the BIO International Convention include the realities of MFN pricing, AstraZeneca's R&D plans for obesity, the need for resources for FDA's rare disease hub and reactions to the Commissioner's National Priority Review Voucher program.

Stock Watch: Generics Firms Trapped Between US Tariffs And European Austerity

 
• By Andy Smith

Successive annual reductions in European drug prices following the pandemic are affecting the global sales of generic pharmaceutical companies. Additionally, the imposition of US import tariffs may result in generic drug supply becoming unprofitable.

UroGen Gets A First-Ever Bladder Cancer Approval Despite US FDA AdComm ‘No’ Vote

 
• By Joseph Haas

UroGen’s Zusduri was approved despite an advisory committee vote recommending against it in May. It is the first approved drug for a type of recurring bladder cancer.

Europe’s Drugmakers Lament EU Pharma Package

 
• By Kevin Grogan

EFPIA says reforms make the continent less attractive for innovative firms.

More from Scrip

BioMarin’s Roctavian Continues to Shine In Hemophilia A Despite Commercial Woes

 
• By Sushmita Panda

Roctavian shows durable bleed control and safety over five years, but high costs and access hurdles limit its commercial outlook.

Dizal’s Zegfrovy Wins US NSCLC Approval, At Lower Dose Than In China

 
• By Dexter Jie Yan

Dizal's EGFR inhibitor Zegfrovy approved in US as new once-daily oral option for second-line NSCLC with EGFR exon 20 insertion mutations, at lower dose than in China.

Novartis’s Cosentyx Suffers Rare Phase III Fail

 
• By Kevin Grogan

Multi-blockbuster falls short in a giant cell arteritis study.